comparemela.com

Latest Breaking News On - Alexis peyroles - Page 1 : comparemela.com

OSE Immunotherapeutics Appoints Alexis Vandier as Chief Executive Officer

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE)is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately.

France generalAlexis peyrolesDominique costantiniAlexis vandierGuillaume van renterghem lifesciThomas guillotFlorence portejoieDarren oplandNantes university hospitalUniversity of economicsBoehringer ingelheimLifesci communicationsVeloxis pharmaceuticals incBusiness developmentRegulatory newsChief executive officer

OSE Immunotherapeutics Reports 2021 Financial Results: Major Progress on its Clinical Programs and a Solid Cash Position to Support its Activities

Shared positive final Phase 3 results for Tedopi in non-small cell lung cancer (NSCLC) patients in secondary resistance after failure with second-line checkpoint inhibitor treatment. Received

United statesFrance generalAlexandre lebeautGuillaume van renterghem lifesciThomas guillotAlexis peyrolesElise chiffoleauDominique costantiniFlorence portejoieDarren oplandEuropean patent officeNantes university at hospitalBoehringer ingelheimAudit committeeAmerican society of hematologyTrademark office

OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Board of Directors

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced the appointment by cooptation of Alexandre Lebeaut as an independent Director of the Company . Alexandre

United statesFrance generalAlexandre lebeautGuillaume van renterghem lifesciThomas guillotAlexis peyrolesDominique costantiniAlexandre lebeautaddedFlorence portejoieDarren oplandNantes university hospitalChildren institute for advanced clinical trialsUniversity of paris descartesBoehringer ingelheimRemuneration committeeLifesci communications

OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Alexis peyrolesDominique costantiniNantes university hospitalBoehringer ingelheimChief executiveChief executive officerLaurence de schoulepnikoffChief business officerChief operating officerNon small cell lung cancerExpansion phaseUniversal registration documentCoronavirus pandemicOse immunotherapeutics saGlobe newswire

OSE Immunotherapeutics Strengthens Leadership Team with the Appointment of Laurence de Schoulepnikoff as Chief Business Officer

In Addition, Three Senior Executives Will Reinforce the Company’s Drug Development Engine .

Silvia comisSanofi evotecAlexis peyrolesDominique costantiniLinda lebonToulouse universityBusiness development at novartisEuropean head of early products medical affairsBoehringer ingelheimSciences aggregationPfizer animal healthCompany as head of clinical developmentFerring internationalBono as senior strategic development directorNantes university hospitalAlliance management

vimarsana © 2020. All Rights Reserved.